Mast Therapeutics, Inc. (MSTX) Reports In-Line Q3 Loss

Mast Therapeutics, Inc. (NYSE: MSTX) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics, Inc. (MSTX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Radnostix revenue falls 27% amid product recalls and FDA actions
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)